Heidelberg Clinical Research Centre Report issue

For profit Phase 2
Founded: Somerset West South Africa (1994)
Status: Acquired by PPD (2014) → now Thermo Fisher Scientific (2021)

Organization Overview

First Clinical Trial
2016
NCT02834364
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

University Clinics Heidelberg

Active Ingredients

Drugs in Phase 2 Trials (4)

avelumab (bavencio) (1 trial)

binimetinib (mektovi) (1 trial)

encorafenib (braftovi) (1 trial)

vxm01 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glioblastoma (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 4